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Summary
Ideally, an oncolytic virus will replicate preferentially in malignant cells, have the ability to treat disseminated metastases,
and ultimately be cleared by the patient. Here we present evidence that the attenuated vesicular stomatitis strains, AV1
and AV2, embody all of these traits. We uncover the mechanism by which these mutants are selectively attenuated in
interferon-responsive cells while remaining highly lytic in 80% of human tumor cell lines tested. AV1 and AV2 were tested
in a xenograft model of human ovarian cancer and in an immune competent mouse model of metastatic colon cancer.
While highly attenuated for growth in normal mice, both AV1 and AV2 effected complete and durable cures in the majority
of treated animals when delivered systemically.
Introduction potent oncolytic virus (Balachandran and Barber, 2000; Stojdl
et al., 2000b). In fact, while VSV infections are uniformly fatal
to nude mice (Huneycutt et al., 1993; Stojdl et al., 2000b), weOver the last decade, a variety of replicating oncolytic viruses
found that prophylactic interferon treatment can rescue evenhave been selected or engineered to be therapeutics that exploit
immunocompromised animals while preserving virus-mediatedgenetic defects unique to tumor cells (reviewed in Bell et al.,
oncolysis. We reasoned that a virus that both induces the pro-2002; Gromeier and Wimmer, 2001; Hawkins et al., 2002; Kruyt
and Curiel, 2002; Norman et al., 2000)). One genetic defect duction of interferon and is susceptible to its antiviral affects
frequently arising during tumor evolution, is diminished inter- would be a superior therapeutic. Here we describe two naturally
feron (IFN) responsiveness (Bello et al., 1994; Linge et al., 1995; occurring VSV variants that possess both these properties. The
Lu et al., 2000; Matin et al., 2001; Sun et al., 1998; Wong et al., VSV variants retain oncolytic activity in vitro and in a variety of
1997). This reflects the important role that interferon-regulated in vivo models but because of their potent induction of interferon
pathways play in the control of normal cell growth and apopto- have a vastly improved therapeutic index over their wild-type
sis. Interferon is also a key mediator of the individual cell’s (WT) counterpart.
antiviral response and thus tumor cells, which acquire mutations
Resultsallowing them to escape interferon-mediated growth control
programs, will simultaneously compromise their innate antiviral
response. We hypothesized that viruses whose replication is Attenuation of VSV in vivo is dependent upon intact
interferon signaling pathwaysinhibited by interferon should grow well in tumor but not normal
cells. We and others have found that vesicular stomatitis virus Two variants of VSV that produce small plaques on interferon-
responsive cells (herein referred to as AV1 and AV2) were found(VSV), whose growth is strongly inhibited by interferon, is a
S I G N I F I C A N C E
A key limitation to the application of viruses as cancer therapeutics is the possibility of uncontrolled virus growth in normal tissues,
potentially leading to treatment complications or disease. Here, we describe novel, oncolytic variants of vesicular stomatitis virus
(VSV) that not only have potent anti-tumor activity in vivo, but establish an anti-viral state that protects against the toxicity associated
with infection of healthy cells. Our work has uncovered the mechanism that virulent VSV strains use to defeat host antiviral defences,
furthering our understanding of early IFN signaling in response to a viral invader. These findings have directed us toward the
development of improved VSV-based oncolytic viruses and are generally applicable to a wide range of viral based therapeutics.
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Figure 1. Decreased in vivo toxicity of AV1 and AV2 is mediated by interferon
A: Human prostate carcinoma cells (PC3) and human renal carcinomas cells (CAKI-1) were either mock infected or infected with wild-type (WT), AV1, or
AV2 strains of VSV. Culture media were assayed by ELISA to detect human IFN- production 48 hr post-infection.
B: Exogenous interferon is required to protect MEFs from WT GFP but not from AV3 GFP. Balb/C MEFs were pretreated with 0 or 30 U/ml universal type I
interferon for 16 hr and then infected with WT GFP VSV or AV3 GFP at an MOI of 0.1. Twenty-four hours later, cell viability was measured by MTS assay.
C: In vivo toxicity of WT versus mutant VSV strains by route and mouse strain. IN  intranasal; IV  intravenous; nd  not determined.
D: AV3 induces IFN- quicker and to a greater degree than WT VSV in vivo. Groups of mice were either mock infected or infected with WT GFP or AV3
GFP, and their serum IFN- levels were assayed at the indicated times post-infection.
E: Balb/C and Balb/C INFAR/ mice were infected intranasally with WT VSV, AV1, or AV2 virus and monitored for morbidity.
F: AV2 can protect mice against lethal WT VSV infection. PKR/ mice were infected intranasally at various doses with either WT, AV2, or both and monitored
for morbidity or mortality. Values denote number of mice per group.
to induce from twenty to fifty times more interferon  (IFN-) tion only in the presence of exogenously added interferon
whereas MEFs (mouse embryonic fibroblasts) are refractory tothan WT VSV following infection of epithelial cell lines (Figure
1A). Sequencing of the variants revealed that they differed from infection by the interferon inducing mutant AV3 (Figure 1B).
In animals, the role of the interferons in protecting againstthe wild-type strain in their M proteins with a single amino acid
substitution in the case of AV1 (M51R) and two amino acids virus infection and the mechanisms underlying their induction
are more complex than in the simple tissue culture systems(V221F and S226R) in AV2. A third variant was created to be a
mimetic of AV1 by complete deletion of methionine 51 (M51 described above (Barchet et al., 2002; Levy, 2002). Neverthe-
less, we show in the following that the AV strains are moreor AV3) and found to have biological properties indistinguishable
from AV1 and AV2. As expected (Stojdl et al., 2000b), primary potent interferon inducers and have reduced toxicity in mice
in a strictly interferon-dependent fashion. For example, micemouse embryo fibroblasts are protected against WT VSV infec-
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infected intravenously can tolerate some 80 times more AV1 In Figures 2C–2E, we present a model in which virus infection
leads to waves of transcriptional events that are sequential andvirus than WT VSV, and AV3 induced a more rapid and robust
interdependent. For example, genes that we refer to herein asproduction of interferon than WT VSV (Figures 1C and 1D). The
primary response genes were induced 3–6 hr post-infectioncritical role that interferon signaling plays in the protection of
by all three viruses (Figures 2B and 2C). On the other hand,mice from infection by AV1 and AV2 was verified using interferon
secondary response genes that require the production of IFN-receptor knockout (INFAR/) animals. The LD50 of AV1 and
protein and the autocrine activation of the JAK/STAT pathwayAV2 when delivered intranasally to Balb/C (INFAR/) mice was
(Figure 2D) were differentially induced by the wild-type anddetermined to be 10,000 times greater than WT VSV delivered
attenuated viruses (see IRF-7 in Figures 2A and 2D). As a conse-by the same route (Figure 1C). Similar results were seen in CD-1
quence of the impaired IRF-7 production in WT VSV-infectedmice (WT  1  106; AV1  2  108 pfu). However, in the
cells, tertiary response gene products like the IFN- transcriptsabsence of a functional interferon receptor, AV1 and AV2 were
were not induced in wild-type VSV-infected cells (Figure 2E).as toxic as wild-type virus, indicating that the attenuation of AV1
These results indicate that all three viruses trigger activation ofand AV2 growth in vivo is dependent upon an intact interferon
IRF-3 and the subsequent transcription of a cohort of genessystem (Figure 1E).
that we call primary response genes. We hypothesized that the
M protein encoded by wild-type VSV disables the host cell’sThe AV1 and AV2 variants protect mice
antiviral response by disrupting subsequent activation of sec-from infection by WT VSV
ondary and tertiary response genes.Mice that lack the double-stranded RNA-dependent kinase
(PKR) gene are known to be exquisitely sensitive to infection by
VSV M protein blocks the nuclear exportwild-type vesicular stomatitis virus, although PKR/ fibroblasts
of interferon- mRNAcan be protected by prophylactic treatment with interferon (Ba-
It has been suggested that VSV M protein either blocks thelachandran et al., 2000). Since AV1 and AV2 strongly induce
transcription of the IFN- gene (Ahmed et al., 2003; Ferran andinterferon production during the course of a natural infection,
Lucas_Lenard, 1997), inhibits the nuclear export of mRNAs (Herwe tested whether PKR/ mice would be resistant to infection
et al., 1997; von Kobbe et al., 2000), or interferes with JAK/by these viruses. Indeed we found that while 10 pfu of wild-
STAT signaling (Terstegen et al., 2001). Our transcript profilingtype VSV can kill PKR/ mice (Figure 1F), doses greater than
studies would be consistent with either of the latter two mecha-107 pfu of AV1 and AV2 were well tolerated by PKR/ animals.
nisms; however, we have been unable to show any impairmentMore strikingly, when coinfected with AV2, the LD100 of wild-
in the induction of the JAK/STAT pathway by exogenous inter-type VSV was dramatically increased in PKR/ animals. Indeed,
feron in infected cells (data not shown). On the other hand,doses 100 times greater than the LD100 for WT VSV were well
when we used microarray or RT-PCR analysis to compare andtolerated when coinfected with AV2 (Figure 1F). Given that
contrast transcripts in nuclear and cytoplasmic fractions, wePKR/ fibroblasts can be protected from WT VSV infection
found clear differences between wild-type and attenuated virus-by prophylactic interferon administration (Balachandran et al.,
infected cells (Figure 3A). Importantly, IFN- mRNA although2000), that the AV variants induce interferon, and that AV vari-
induced in nuclear fractions by all three viruses was not foundants are toxic in mice that lack a functional interferon receptor,
in the cytoplasmic pool of mRNAs in WT infected cells. Further-we believe that the protective effect of AV2 on PKR/ mice is
more, IFN- was undetectable in culture media from cells in-most easily explained by the ability of these viruses to strongly
fected with WT VSV, while copious amounts of the cytokineinduce interferon production in the infected animal.
were produced from cells infected with either AV1 or AV2 (Figure
3B). Two additional experiments help shed light upon how WTWild-type, AV1 and AV2 viruses trigger antiviral
VSV subverts the interferon signaling pathway. First, cells were
responses in infected cells
infected with either WT or AV3 VSV, and at 22 hr post-infection,
We used microarray and Western blot analysis over a time- IFN- production in tissue culture supernatant was measured.
course of virus infection to allow us to detect early signaling WT VSV does not induce the production of IFN- while AV3 is
events triggered by WT and AV variants that lead to the tran- a potent inducer (Figure 3C). The induction of IFN- by AV3
scriptional activation of antiviral genes. Others have established was dependent upon prior production of IFN- as inclusion of
that an early response to virus infection is the phosphorylation neutralizing anti-IFN- antibody to infected cultures inhibited
and activation of the latent transcription factor IRF-3 (Sato et IFN- production from these cells (Figure 3C). Second, we con-
al., 1998b). It appears that WT, AV1 and AV2 viruses trigger structed a wild-type VSV that expresses a constitutively active
IRF-3 phosphorylation with similar kinetics (Figure 2A). Follow- version of IRF-7. This virus has an attenuated phenotype and
ing phosphorylation, IRF-3 assembles together with CBP/300 induces the expression of IFN- genes within 4 hr post-infection,
and, along with other transcription factors (e.g., NF	B and even in the presence of wild-type VSV M protein (Figure 2D).
c-JUN/ATF-2), initiates the transcription of a number of antiviral In total, these results are consistent with the idea that wild-type
gene products (Wathelet et al., 1998). As shown in Table 1, VSV triggers a primary antiviral response, but through coordi-
microarray analysis revealed that a large number of genes were nate expression of viral gene products blunts secondary and
dramatically induced 3 hr post-infection with all three viruses. tertiary responses by blocking nuclear export of critical antiviral
Many of these genes are known to be activated by virus infection mRNAs.
(Nakaya et al., 2001), including several that are directly regulated
following activation of the latent transcription factors IRF-3, AV1 and AV2 retain their ability to kill tumor
NF	B, and c-JUN/ATF-2 (Genin et al., 2000). We validated the cells in vitro and in vivo
microarray data by performing RT-PCR analysis on a sampling To assess the oncolytic properties of the attenuated VSV strains,
the NCI human tumor cell panel (60 cell lines from a spectrumof gene products (Figure 2B).
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Figure 2. The secondary transcriptional response is inhibited by WT VSV but not AV1 or AV2
A: Western blot analysis showed similar kinetics of IRF-3 activation between WT and mutant VSVs; however, ISG56 (primary response) protein expression
was severely impaired in WT infected cells. IRF-7 protein is detected only in AV1- and AV2-infected cells. IRF-7 appears to be able to induce the expression
of endogenous IRF-7.
B: RT-PCR data at 4 hr post-infection of A549 cells showed primary response genes RANTES and IFN- induced to similar levels in WT and mutant VSV-
infected cells while upregulation of MX1 (secondary response) was impaired in WT infected cells.
C: Primary response to viral infection is mediated by IRF-3, cJUN/ATF-2, and NF	B (shown here forming part of the enhancesome complex at the IFN-
promoter). Microarrray data indicate primary transcriptional response genes robustly upregulated in both WT and mutant virus-infected cells. (a: ISG15 is
known to require ISGF3 for full induction). Values represent fold induction over mock infected.
D: IFN- is then translated and secreted to stimulate, in an autocrine fashion, JAK/STAT signaling to form ISGF3 complexes in the nucleus, which mediates
the induction of genes of the secondary transcriptional response. While cells infected with AV1 or AV2 show robust upregulation of these genes, WT infected
cells show no expression at all (A  absent).
E: Without the consequent expression of IRF-7 in cells infected with WT VSV, the tertiary transcriptional wave, which includes almost all IFN- genes, cannot
take place (b: IFN-7 is marginally detected by the array in WT samples). In contrast, AV1- and AV2-infected cells efficiently induce the expression of IFN-
genes.
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Table 1. Microarray analysis of the transcriptional response to VSV infection over time
WT AV1 AV2
Hours post infection Hours post infection Hours post infection
Accession # Common name 3 6 12 3 6 12 3 6 12
Primary transcriptional response
NM 000201.1 CD54 2.3 A A 3.3 3.0 33.6 2.7 5.4 56.8
NM 016323.1 CEB1 2.0 21.2 204.4 1.6 38.0 279.3 1.9 73.6 490.5
U83981 GADD34 10.8 57.5 95.0 3.1 48.8 422.7 5.5 159.0 686.7
NM_002176.1 IFN beta 4.2 103.2 488.6 3.2 154.5 1531.6 3.6 487.3 2157.9
NM 000600.1 IL6 7.3 19.1 38.2 3.8 44.7 171.6 7.4 120.3 238.7
BE888744 ISG54 19.5 173.1 804.5 4.7 141.0 721.9 11.4 268.4 1357.8
NM_00 1548.1 ISG56 32.3 285.9 855.2 20.0 456.8 1411.7 39.8 766.0 1992.1
NM_00 1549.1 ISG60 7.6 57.5 238.0 4.1 97.7 288.6 7.0 151.6 457.7
AF063612.1 OASL 6.6 71.8 222.0 3.4 81.9 388.9 5.7 172.0 776.9
NM_021127.1 PMAIP1 5.2 22.1 58.6 2.1 17.3 87.5 4.3 34.3 169.8
NM_002852.1 PTX3 5.9 3.1 A 6.4 11.7 114.0 4.9 29.9 117.6
AF332558.1 PUMA 10.6 A A A 38.7 211.6 9.8 77.8 428.0
NM 002985.1 RANTES 3.4 60.1 945.0 2.6 84.9 1796.7 4.1 301.8 3916.1
AY029 180.1 SUPAR 3.7 9.8 14.7 2.4 10.5 40.5 2.8 27.7 46.3
NM_006290.1 TNFAIP3 2.8 6.3 15.5 2.7 13.8 83.5 3.1 30.5 152.8
Secondary transcriptional response
NM_030641.1 APOL6 A A A A 15.3 40.8 A 25.2 37.3
AF323540.1 APOLL 1.8 A A 1.0 11.3 25.7 2.2 10.7 34.5
U84487 CX3C chemokine precursor 2.0 2.5 2.5 1.7 7.0 45.1 2.3 14.1 65.9
BC002666.1 GBP1 A A 4.2 A 35.9 171.6 1.4 66.2 249.2
NM_006018.1 HM74 A A A 2.2 29.1 72.5 A 66.4 45.4
NM_031212.1 hMRS3/4 A A A 2.5 4.2 21.3 A 10.1 18.3
NM 005531.1 IFI16 A A A 2.4 12.8 38.1 2.8 18.9 46.2
NM_005532.1 IFI27 A A 21.9 A 36.6 281.0 A 51.0 295.4
NM 004509.1 IFI41 A A A A 10.0 22.8 1.3 11.9 18.1
NM_022873.1 IFI-6-16 0.9 2.5 2.2 0.7 7.0 15.6 1.1 9.6 15.7
NM_003641.1 IFITM1 1.9 A A 1.2 8.5 67.1 1.9 14.3 42.1
AA749101 IFITM1 1.2 3.1 2.3 1.0 6.6 40.9 1.2 9.5 32.6
NM 000882.1 IL12A 1.6 A A A 4.9 13.7 A 6.5 28.8
M15329.1 IL1A nd A A A 8.3 79.4 A 27.0 287.6
NM_004030.1 IRF7 1.4 A A A 19.9 109.9 2.2 33.7 144.3
NM_006084.1 IRF9 A A 1.2 1.6 6.5 11.2 1.5 7.8 17.4
BC001356.1 ISG35 1.1 A A 1.0 5.8 23.2 1.4 7.1 20.2
AF280094.1 ISG75 1.3 1.8 2.2 1.5 10.3 16.2 1.2 12.5 13.8
AF280094.1 ISG75 0.9 1.7 A 1.2 7.5 10.8 1.5 9.5 11.1
U 17496.1 LMP7 A A A A 7.6 15.3 0.9 10.0 10.4
NM_006417.1 MTAP44 A A 23.3 A 10.8 82.7 A 18.0 133.9
NM_002462.1 MX A A A 27.6 A 48.1 261.9 A 85.7 232.9
AB014515 NEDD4 BP1 A A 9.2 2.0 4.0 13.1 1.5 4.5 19.5
NM_002759.1 PKR 0.5 0.9 2.0 0.8 4.3 15.2 1.0 6.6 9.6
NM_021 105.1 PLSCR1 1.4 1.7 A 2.2 5.0 24.9 2.1 4.9 15.1
NM_017912.1 putative Ub ligase A A 19.1 A 9.6 26.3 A 12.5 24.8
BF939675 SECTM1 A A A A 20.7 93.8 A 24.8 33.9
BC004395.1 Similar to apolipoprotein L A A A A 11.7 17.2 A 14.6 21.3
NM_003141.1 SSA1 A A A 1.2 5.9 11.2 1.4 7.9 11.1
AA083478 STAF50 nd A nd 1.7 8.5 96.3 nd 16.7 56.1
NM_005419.1 STAT2 1.1 A A 1.3 3.0 9.1 1.1 4.3 9.1
NM_003810.1 TRAIL A A A A 22.4 135.4 0.7 37.3 88.6
NM_020119.1 ZAP A A 19.4 0.9 4.6 79.9 A 11.4 133.8
Tertiary transcriptional response
M 12350.1 IFN-27 A A A nd nd 102.3 nd A 101.4
NM_024013.1 IFNA1 nd A A nd 2.2 53.6 nd A 44.0
NM_002171.1 IFNA10 A A A A A 96.2 A A 55.1
NM_006900.2 IFNA13 A A A A A 165.4 nd A 152.1
NM_002 172.1 IFNA14 A A A A A 159.0 A 4.4 91.1
NM_002 173.1 IFNA16 1.0 A 1.8 1.1 0.9 139.9 0.7 3.3 95.7
M38289.1 IFNA17 A A A A A 21.5 A A 19.8
NM_002 169.1 IFNA5 1.0 A A 0.9 A 16.4 0.9 A 11.6
NM_021057.1 IFNA7 A A 3.5 A A 105.0 A 3.4 61.7
Data represented as fold change compared to mock-infected samples. All samples are from nuclear fractions of infected cells.
A  Absent (no detectable mRNA); nd  no data; bold genes represent “archetypal genes,” see text for explanation.
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of malignancies) was challenged with either WT, AV1, or AV2
viruses and assayed for metabolic cell death 48 hr later. It is
clear from Table 2A that WT VSV is able to infect and kill a wide
range of cancer cell types, and furthermore, the majority of
cancer cell lines tested demonstrated impaired responses to
either IFN- or IFN- (Table 2B). AV1 and AV2 were as effective
at killing these interferon nonresponsive tumor cell lines as WT
VSV.
We previously reported the successful treatment of subcuta-
neous xenograft tumors in nude mice with WT VSV; however,
in these experiments, exogenous interferon was required to
protect the animals from succumbing to viral infection. Our
results with the NCI cell panel suggest that AV1 and AV2 should
efficiently kill tumor cells with little toxicity in mouse models
even in the absence of interferon treatment, and therefore we
conducted an extensive analysis of the in vivo oncolytic proper-
ties of the AV variants. In a first series of experiments, human
ovarian carcinoma cells were injected into the peritoneal cavity
of CD-1 nude mice and allowed to grow for 12 days. Mice (14/
15) receiving UV-inactivated virus developed ascites by day 15
post-treatment. In contrast, three doses of AV2 delivered into
the peritoneal cavity provided durable cures in 70% of the mice
(Figure 4A). Remarkably, while a single therapeutic dose of WT
VSV is uniformly lethal to nude mice (Stojdl et al., 2000b), none
of the animals treated with three doses of AV2 exhibited even
symptoms of virus infection.
Systemic treatment in immune-competent
mouse models
Earlier preclinical, clinical, and mathematical modeling studies
(Wein et al., 2003) predict that greatest anti-tumor efficacy is
achieved when the delivered virus is distributed diffusely
throughout the tumor (e.g., through tumor vasculature). Given
that certain oncolytic viruses are rapidly inactivated in blood or
inhibited by physical barriers (Ikeda et al., 2000; Wakimoto et
al., 2002, 2003; Yoon et al., 2001), we felt it was important to
determine the minimum VSV doses required to achieve effective
delivery of VSV into tumor sites. For these studies, we engi-
neered a VSV strain to express GFP during productive infections
and examined subcutaneous tumors 24 hr after intravenous
virus administration. Virus doses in the range of 108–109 pfu
per mouse gave optimum tumor delivery (Figure 5). In other
experiments and those shown below, we found that virus admin-
istered in this dose range also provided maximum therapeuticFigure 3. WT VSV inhibits IFN- mRNA nuclear/cytoplasmic transport and
benefit to tumor-bearing animals. For example, subcutaneousblocks IFN- production
tumors were established by injecting CT26 colon carcinomaA: IFN- mRNAs are severely depleted in cytoplasmic fractions from WT
cells into the hind flank of syngeneic Balb/c mice. Once tumorsVSV-infected cells as determined by quantitative RT-PCR. Nuclear (N) and
cytoplasmic (C) total RNA fractions from cells infected with WT, AV1, or AV2 became palpable (approximately 10 mm3), virus was adminis-
VSV were assayed for IFN-mRNA, normalized to HPRT mRNA from the same tered via tail vein injection. Twelve days post-treatment, mice
sample. * indicates no IFN- mRNA detected.
receiving UV-inactivated VSV reached endpoint with an averageB: Cells infected with either WT or mutant VSV strains were assayed by ELISA
tumor size of 750 mm3. In contrast, a single treatment with AV2for IFN- production. AV1- and AV2-infected cells and not WT VSV-infected
cells produce secreted IFN-. showed significant efficacy, delaying the time to endpoint by
C: Blocking IFN- inhibits the production of IFN-. OVCAR-4 cells were in- almost 3-fold (34 days). Of the eight animals in this treatment
fected with mutant VSV in the presence of neutralizing antibody to IFN- group, seven were considered partial responders while only oneor an irrelevant antibody and subsequently assayed by ELISA for IFN- pro-
mouse did not respond to the treatment (data not shown). Whenduction.
multiple doses of AV1 or AV2 were given intravenously, the
efficacy of the treatments was markedly increased (Figure 4B).
With the exception of one animal, all tumors responded to treat-
ment with AV1, with 3/6 mice showing complete tumor regres-
sion. Two of these mice showed complete regressions as early
as day 8 and 9, respectively, post-infection. Two of the re-
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Table 2A. Mutant VSV strains are highly lytic on members of the NCI 60 panel of cancer cell lines
WT AV1 AV2
MOI MOI MOI
Leukemia 67% (4/6)* 0.13 nd 60% (3/5) 0.02
NSC lung carcinoma 78% (7/9) 0.02 60% (3/5) 0.001 75% (6/8) 0.19
Colon carcinoma 86% (6/7) 0.037 100% (5/5) 0.001 100% (6/6) 0.017
CNS 80% (4/5) 0.02 50% (1/2) 0.6 60% (3/5) 0.38
Melanoma 75% (6/8) 0.1 100% (2/2) 0.15 63% (5/8) 0.25
Ovarian carcinoma 100% (6/6) 0.3 67% (2/3) 0.0005 60% (3/5) 0.14
Renal carcinoma 88% (7/8) 0.24 100% (3/3) 0.14 100% (7/7) 0.48
Prostate 100% (2/2) 0.06 100% (2/2) 0.035 100% (2/2) 0.04
Breast 83% (5/6) 0.009 75% (3/4) 0.005 60% (3/5) 0.12
All cell lines tested 82% (47/57) 0.11 80% (21/26) 0.07 75% (38/51) 0.20
*Percent of NCI 60 panel cell lines by tumor type deemed highly sensitive to virus infection. () denote the number of highly susceptible cell lines out of the
number of cell lines tested. Cell line deemed highly susceptible if the EC50 
 MOI of 1 following a 48 hr infection. MOI represents average EC50 (MOI) of
susceptible cell lines. nd  not determined.
maining animals showed partial responses, delaying tumor pro- prior to the time of sacrifice had lungs with normal mass and
gression by almost 2-fold compared to controls. All eight AV2- few obvious tumor nodules (Figure 4D). Consistent with this
infected mice responded well to treatment with five of eight result, viral gene expression could be detected within 24 hr of
developing durable tumor regressions. In fact, no sign of tumor a single intravenous dose of GFP-expressing AV3 in all tumor
regrowth was evident even 7 months post-treatment. Further- nodules, with little or no detectable expression in normal lung
more, these mice failed to produce tumors when rechallenged tissue (Figure 4D; inset).
with CT26 cells 7 months post-treatment, with no trace of de- Figure 4E shows the survival plots of mice seeded with lung
tectable virus, perhaps indicating that host-mediated immunity tumors and then treated intranasally with UV-inactivated virus,
to the tumor had developed. All forms of intravenous treatment AV1 or AV2. The mean time to death (MTD) of animals treated
were well tolerated by the mice, with no mortalities occurring and with UV-inactivated virus was approximately 20 days. However,
minimal signs of morbidity. Infected mice had mild to medium mice treated with either AV1 or AV2 were completely protected.
piloerection, mild dehydration, and some transient body weight This experiment demonstrates the remarkable ability of AV1 and
loss following the initial treatment (Figure 4C). These symptoms AV2 to produce durable cures in an aggressive, disseminated,
were only observed after the initial infection, and all subsequent immune-competent tumor model.
doses failed to elicit any signs of infection.
Discussion
Systemic administration of AV1 and AV2 is effective
against disseminated disease A key difference between the attenuated viruses described here
CT-26 cells, when injected into the tail vein, seed tumors and previously reported oncolytic versions of VSV is the inability
throughout the mouse, although predominantly within the lungs. of mutant M proteins of the AV viruses to block interferon pro-
We examined the lungs of four mice 16 days after tumor cell duction in infected cells. VSV M is a multifunctional protein
injection and four days after treatment with UV-inactivated virus required for several key viral functions including budding (Jaya-
(Figure 4D). These lungs were three times their normal mass kar et al., 2000), virion assembly (Newcomb et al., 1982), cyto-
due to their tumor burden. In contrast, tumor-bearing littermates pathic effect (Blondel et al., 1990), and inhibition of host gene
receiving a single intravenous or intranasal dose of AV2 4 days expression (Lyles et al., 1996). The latter property has been
attributed to the ability of M to block host RNA polymerase
activity (Ahmed et al., 2003; Yuan et al., 2001) or to inhibit the
nuclear transport of both proteins and mRNAs into and out ofTable 2B. The majority of cell lines in the NCI 60 cell panel show IFN defects
the host nucleus (Her et al., 1997; von Kobbe et al., 2000). The
Type I IFN defects
results presented here using virus infection are consistent with
Leukemia 100% (6/6)* blocks in nuclear transport being the major mechanism by which
NSC Lung carcinoma 71% (5/7)
wild-type VSV strains mitigate host antiviral response. Our anal-Colon carcinoma 100% (7/7)
ysis of infected cell transcripts provided little evidence to sup-CNS 75% (3/4)
Melanoma 85% (6/7) port a role for M protein in inhibiting host cell transcription
Ovarian carcinoma 67% (4/6) but rather shows that VSV infection triggers an IRF-3-mediated
Renal carcinoma 75% (6/8) stimulation of antiviral genes followed by an M protein-mediatedProstate 100% (2/2)
block of transport of primary response transcripts from infectedBreast 60% (3/5)
All cell lines tested 81% (42/52) cell nuclei. Particularly germane to this study is the work from
Dahlberg’s group (Petersen et al., 2000) and others (von Kobbe*Denotes the number of cells in each group, which were unresponsive to
either IFN- or IFN- pre-treatment. Cell line deem unresponsive if IFN pre- et al., 2000) that has shown, by transfection studies, that M
treatment was unable to significantly affect (10-fold) the EC50 of cells protein can associate with nuclear pore proteins and effect a
infected with WT VSV for 48 hr. block in mRNA export possibly through an association with the
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Figure 4. AV strains are efficacious in mouse tumor models
A: AV2 is effective in treating human ovarian tumor xenografts. 1  106 human ES-2 ovarian carcinoma cells were injected into the intraperitoneal cavity
of CD-1 nude mice. Twelve days later, animals were treated by intraperitoneal injection every other day with either AV2 or UV-inactivated AV2 (1  109
pfu/dose; three doses total). Animals were assessed for morbidity and mortality and euthanized following the appearance of moderate ascites formation.
“n” denotes number of animals per group.
B: Intravenous treatment of subcutanenous tumors. Tumors were established in the hind flank of Balb/C mice by injecting 1  106 CT26 cells. When tumors
reached approximately 10 mm3, mice were treated every other day for 10 days (six doses total) with an intravenous injection of 5  108 pfu of the indicated
virus. Control mice received six doses of 5  108 pfu equivalents of UV-inactivated AV2 VSV. Tumors were measured daily to calculate tumor volumes and
animals were euthanized when tumors reached approximately 750 mm3. Error bars denote SEM.
C: Mouse weights measured daily, for each treated group, for the 3 days before treatment to day 11 post-treatment. Error bars denote SEM.
D: Treatment of disseminated lung tumors. Lung tumors were established by injecting 3  105 CT26 cells into the tail vein of Balb/C mice. On day 12, mice
were treated as follows: UVAV2 IV  1 dose intravenously (5  108 pfu equivalents), AV2 IV  1 dose AV2 intravenously (5  108 pfu), AV2 IN  1 dose of
AV2 intransally (5  107 pfu). Four days after treatment, all mice were sacrificed and their lungs were removed (hearts are visible for scale). Arrows indicate
residual tumors. Inset: mice bearing CT-26 lung tumors were infected with AV3 GFP, and the lungs were removed and visualized as indicated.
E: Lung tumors were established as described above. On day 12, mice received 5  107 pfu of AV1 or AV2 by intranasal instillation every other day for 2
weeks (six doses total). “n” denotes number of mice in treatment group.
interferon-inducible cellular gene product Nup98. Indeed others note that in yeast, specific mRNA export factors (Yra1 and
Mex67) have been shown to be responsible for the transporthave suggested that overexpression of Nup98 following inter-
feron treatment may be sufficient to overcome an M-induced of different groups of transcripts (Hieronymus and Silver, 2003).
Yra1 exports transcripts depending upon their rate of transcrip-block of mRNA export. Interestingly, when we compared tran-
script levels in nuclear and cytoplasmic fractions following virus tion whereas the Mex67 export protein does not discriminate
on this basis (Hieronymus and Silver, 2003). Perhaps M proteininfection, we detected that nuclear export defects were more
pronounced on some transcripts than others (D.F.S. and J.C.B., in conjunction with Nup98 is targeting a specific set of proteins
involved in the regulation of export of a subset of nuclear tran-data not shown), which may reflect that the M-induced block
may be specific for a subset of transcripts. It is interesting to scripts.
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Figure 5. Threshold dose required for systemic delivery to subcutaneous tumors
Balb/C mice bearing CT26 subcutaneous tumors were treated with AV3 GFP intravenously at the indicated dose. At 24 hr, tumors were examined for
fluorescence under a dissecting microscope. Tumors are shown in black and white, overlayed with fluorescent image.
It appears that host cell antiviral programs are initiated by not sufficient to protect against lethal infections. The results
presented here and elsewhere (Barchet et al., 2002) are consis-activation of the latent transcription factors NF	B, c-JUN/ATF2,
and IRF-3. Upon viral entry into the host cell, the transcription tent with the idea that the rapid and robust local stimulation of
interferon by AV strains in mice successfully attenuates virusfactors c-JUN and IRF-3 are phosphorylated by JNK and a
recently identified virally activated kinase (Sharma et al., 2003), replication in normal tissues (even of WT VSV, see Figure 1F).
Our data indicates that defects in interferon signaling frequentlywhile NF	B is released from its inhibitor IkB through the action
of upstream IKK(s) (DiDonato et al., 1997). The activated tran- occur during tumor evolution, with a majority of the cell lines in
the NCI panel having an impaired response. Accumulating datascription factors translocate to the nucleus and coordinately
form an enhancesome complex at the IFN- promoter, leading have indicated that interferon is a multifunctional cytokine that
can coordinately regulate cell growth, apoptosis, and antiviralto IFN- induction (Wathelet et al., 1998). Here we refer to this
as the primary transcriptional response to virus infection. We pathways. Perhaps during tumor evolution, the selection for
relentless growth and loss of apoptosis outstrips the occasionaland others (Levy, 2002; Sato et al., 1998a) postulate that a
secondary transcriptional wave (or positive feedback loop; Levy, need for antiviral activity.
Kirn and colleagues argue that several factors are important2002) is triggered by the IFN--dependent induction of a variety
of interferon-stimulated genes. The data presented here with in tumor killing by oncolytic virus therapeutics, including the
effective delivery to multiple sites within the tumor, evasion ofwild-type M protein help to delineate the distinction between
these primary and secondary transcriptional events as well as acquired and innate immunity, and rapid virus growth and
spread (Wein et al., 2003). We have found that intravenousidentify several novel viral response genes (GADD34, PUMA).
Following infection with viruses harboring mutant M proteins, administration of VSV is an effective means of delivering virus
to multiple sites within the tumor, and because of its broadit becomes clear that autocrine stimulation of the JAK/STAT
signaling pathway by IFN- leads to the production of secondary tissue tropism and short replicative cycle, VSV can rapidly grow
and spread within the tumor. These same traits, however, canresponse genes like IRF-7, which in turn are critical for the
tertiary induction of IFN- genes (Morin et al., 2002). Indeed the be a lethal combination if virus growth in normal tissues is
unchecked (Figures 1B and 1C). The attenuated viruses de-M protein block of secondary and tertiary transcripts can be
overcome by expressing a constitutively active version of IRF-7 scribed here provide the best of both worlds; they grow rapidly
in a broad spectrum of tumor cells but, because of their ability(from a viral promoter) even in the presence of wild-type M
protein. While our cell culture studies clearly delineate the role to trigger antiviral responses in normal cells, may be exception-
ally safe to the treated animal.of VSV M in blunting the positive feedback loop that is depen-
dent upon production of IFN- and a functional interferon recep- One concern about the use of oncolytic virus therapeutics
is the idea that a virulent strain could arise during virus propaga-tor, WT VSV infection still is capable of inducing interferon in
intact animals (albeit more slowly and to lower levels). Others tion in a tumor. It is of interest to note, however, that it has
proven impossible to date to select for VSV variants that arehave shown that in virus-infected animals, an IFN--independent,
systemic induction of interferon can occur in certain dendritic resistant to the antiviral effects of interferon (Novella et al., 1996),
and we have shown that IFN-inducing mutants protect the hostcell subsets; however, it is the local IFN--dependent produc-
tion of interferon that is critical in determining the magnitude and against infection with WT VSV (Figure 1F). Others have found
that M mutations of the type described here cannot be comple-ultimate success of an interferon-mediated antiviral response
(Barchet et al., 2002). We show that the amount of interferon mented by mutations in other parts of M or other VSV genes
(Coulon et al., 1990). In other words, only true revertants thatand the timing of its production in WT VSV-infected animals are
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gated to the single-stranded RNA genome of the HR strain of VSV. Reverse
transcription coupled PCR was used to clone the entire genome as fragments
into the pBluescript II SK vector (Stratgene). The PCR primers were de-
signed in such a manner as to introduce unique restriction endonuclease
sites between each of the five viral cistrons. Ligation of these fragments
resulted in the construction of a full-length positive sense copy of the HR
VSV genome with a T7 promoter sequence at the 5 end of this anti-genome.
Two overlapping oligonucleotides were synthesized to correspond to the
hepatitis delta virus ribozyme sequence such that an XhoI site was introduced
at the 3 terminus of the ribozyme to facilitate further cloning. These oligos
were annealed and extended using Klenow to form a blunt-ended double-
stranded DNA fragment. A 300 bp fragment from the 3 terminus of the anti-
genome was PCR amplified and blunt end cloned to the ribozyme fragment.
This fragment was subsequently cloned into the full-length genome construct
described above via an internal AflII site in the 3 terminus of the viral genome,Figure 6. Model depicting how mutant VSV strains protect against virus
and the XhoI site engineered into the ribozyme fragment. Finally, the T7spread
terminator sequence was cloned into this vector using the flanking XhoI andA: WT VSV blocks IFN production from infected cells. Uninfected cells are
BssHII sites. This plasmid was designated pDSV1. To generate AV3VSV,not protected from virus spread.
we removed a XhoI/KpnI fragment spanning a region from within the P geneB: VSV strains defective in blocking nuclear/cytoplasmic mRNA export po-
to within the G gene of pDSV1, replacing a similar fragment from withintently induce a “cytokine cloud” of antiviral cytokines (e.g., IFNs) protecting
pXN, yielding the plasmid pXNDG. This facilitated the exchange of the Mneighboring cells from virus spread.
cistron from pXNDG, with one previously mutated by deleting the codon
for methinonine at position 51 in the amino acid sequence using directed
mutagenesis (Quickchange XL; Stratgene). Subsequently, the GFP coding
sequence was removed from pEGFP (Clontech) by digesting with XhoI and
convert arginine 51 back to methionine 51 can restore mutant XbaI and ligated into XhoI and NheI sites downstream of the additional stop/
M back to the wild-type phenotype. One of the viruses we start sequence in the pXNDG vector.
have used in this work is a complete deletion of methionine 51, WT GFP VSV was constructed by inserting the coding region of GFP
from pEGFP (Clontech) between the XhoI and NheI sites in the pXN vectormaking the possibility of reversion to wild-type, even following
(provided by John Rose).several rounds of replication, remote. We speculate that in any
population of interferon-responsive viruses where the majority
IFN ELISAof particles are potent inducers of interferon, it is unlikely that
Interferon- levels were measured using a Human Interferon-Alpha ELISA
a wild-type variant could rise to dominance. The resulting “cyto- kit (PBL Biomedical) per manufacturer’s directions. Various cell lines were
kine cloud” produced by infection with the IFN-inducing virus infected with either WT VSV or AV1 or AV2 VSVs at an MOI of 10. One
hundred microliters of culture medium was collected at 48 hr post-infectionwould protect the normal tissues of the host from the more
and incubated in a 96-well microtiter plate along with standards suppliedvirulent WT strain (Figure 6). Tumor killing would, however, be
by manufacturer. IFN- production was measured at 10 hr post-infectionunaffected, as we have shown the majority of malignancies to
using a human IFN- detection kit (TFB INC; Tokyo, Japan). Samples werebe defective in responding to such a “cytokine cloud.” We sug-
processed as per manufacturer’s instructions and then read on a DYNEX
gest that oncolytic viruses that trigger but do not disable antiviral plate reader at primary wavelength of 450 nm with a reference wavelength
responses will have a significantly improved therapeutic index of 630 nm.
over viruses that lack this property. A variation of the above assay was used to determine the impact of
IFN- on IFN- production. Briefly, 24-well plates of OVCAR-4 cells were
Experimental procedures either mock infected or infected with WT GFP VSV or AV3 GFP VSV at an
MOI of 5 for 30 min. These wells were then washed with PBS and fed with
Viruses OptiMEM (Invitrogen) or OptiMEM supplemented with various concentra-
The Indiana serotype of VSV was used throughout this study and was propa- tions of antibody as indicated. To neutralize IFN- in the media, an anti-
gated in Vero cells. T1026R (Desforges et al., 2001) and TP3 (Desforges et IFN- antibody was used (AHC4024; Biosource International), and as a
al., 2001), herein referred to as AV1 and AV2, respectively, were shown in nonspecific control, an anti-HA antibody was used (sc-805; Santa Cruz).
this study and elsewhere to be IFN-inducing mutants of the HR strain of Twenty-two hours post-infection, 100 l of media from each well was as-
wild-type VSV Indiana (Francoeur et al., 1987). WT GFP and AV3 GFP are sayed for IFN- production using a Human IFN- ELISA (PBL Biomedical)
recombinant viruses rescued from plasmids described below. The rescue kit as described.
procedure has been described in detail elsewhere (Lawson et al., 1995). Mouse serum IFN- levels were assayed using a mouse Interferon-
Alpha ELISA kit (PBL Biomedical). Balb/C females (10 weeks old; Charles
River) were injected intravenously with either PBS or 1  108 pfu of WT GFPConstructs and viral rescue
or AV3 GFP diluted in PBS. At the indicated times post-infection, blood wasCreation of the constitutively active IRF-7 (IRF-7 247467) has been
collected from the saphenous vein of each mouse into heparinized tubespreviously described elsewhere (Lin et al., 2000). IRF-7 247467 was
and centrifuged to obtain serum. For each sample, 5 l of serum was dilutedamplified by PCR using a forward primer to the Flag epitope with an additional
in 95 l of PBS and assayed as per manufacturer’s instructions.5 VSV cap signal and an Xho1 linker (ATCGCTCGAGAACAGATGACTA
CAAAGACGATGACGACAAG), together with a specific IRF-7 reverse primer
containing a VSV poly A signal and an Nhe1 linker (ATCGGCTAGCAGTTTTT Determination of in vivo toxicity of VSV mutant viruses
TTCAGGGATCCAGCTCTAGGTGG GCTGC). The PCR fragment was then Eight- to ten-week-old female mice (strains as indicated; Charles River) were
cloned into the XhoI and NheI sites of the rVSV replicon vector pVSV-XN2 divided into groups of five and infected with dilutions of virus from 1  1010
(provided by John Rose). Recovery of rVSV has been previously described pfu to 1  102 pfu by the indicated route. Animals were monitored for weight
(Lawson et al., 1995). loss, dehydration, piloerection, huddling behavior, respiratory distress, and
AV3 GFP is a recombinant virus with a deletion of methionine 51 in the hind limb paralysis. Mice showing moderate to severe morbidity were eu-
M protein, as well as an extra cistron-encoding green fluorescent protein thanized as per good laboratory practices prescribed by the CCAS. Lethal
(GFP) inserted between the G and L sequences. Using T4 RNA ligase, an dose 50 values were calculated by the Karber-Spearman method.
Four-week-old Balb/C mice or Balb/C interferon- receptor knockoutoligonucleotide containing a consensus T7 polymerase sequence was li-
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mice (IFNAR/) (Steinhoff et al., 1995) were infected intranasally with 104 infections (data not shown). Primers used to amplify IFN- were sense
5-TTGTGCTTCTCCACTACAGC-3; antisense 5-CTGTAAGTCTGTTAATpfu of either WT VSV, AV1, or AV2. Mice were monitored for signs of morbidity
and were euthanized upon signs of severe respiratory distress. GAAG-3 and HPRT primers were sense 5-TGACACTGGCAAAACAA
TGCA-3, antisense 5-GGTCCTTTTCACCAGCAAGCT-3.
Determination of in vivo toxicity of mixed samples
of WT and mutant VSV strains RT-PCR of interferon- and interferon-stimulated genes
A549 cells cultured in F12K medium supplemented with 10% FBS wereGroups of three mice were infected by intranasal instillation with either WT,
AV2, or mixtures of these strains as indicated. Mice were monitored for infected with WT or AV strains (MOI 10). RNA was extracted 4 hr post-
infection using Trizol (Invitrogen) according to the manufacturer’s instruc-signs of morbidity and were euthanized upon signs of severe respiratory
distress or hind limb paralysis. tions. One microgram of RNA was reverse transcribed with Oligo dT primers
and 5% of RT was used as template in a Taq PCR. Primers used were as
follows: Mx forward primer 5-TTGTTGTTTCCGAAGTGGAC-3 and reverseMTS assay
primer 5-TTTCTTCAGTTTCAGCACCAG-3; VSV N forward primerIn each experiment, the test cell line was seeded into 96-well plates at 3 
5-ATGTCTGTTACAGTCAAGAGAATC-3 and reverse primer 5-TCATTTGT104 cells/well in growth medium (DMEM-F12-HAM  10% FBS; Invitrogen).
CAAATTCTGACTTAGCATA-3; RANTES forward primer 5-TACACCAGTGFollowing overnight incubation (37C, 5% CO2), media were removed by
GCAAGTGCTCCAACCCAG-3 and reverse primer 5-GTCTCGAACTCCTaspiration and to each well was added 20 l of virus-containing media
GACCTCAAGTGATCC-3; -actin forward primer 5-ACAATGAGCTGC(-MEM, no serum) ranging in 10-fold increments from 3  106 pfu/well to
TGGTGGCT-3 and reverse primer 5-GATGGGCACAGTGTGGGTGA-3.3 pfu/well or negative control media containing no virus. Each virus dose
tested was done in replicates of six. After a 60 min incubation to allow virus
attachment, 80 l of growth medium was added to each well, and the plates Ovarian xenograft cancer model in athymic mice
Approximately 1  106 ES-2 human ovarian carcinoma cells were injectedwere incubated for another 48 hr. Cell viability was measured using the
into the peritoneal cavity of CD-1 athymic mice (Charles River). AscitesCellTitre 96 AQueous MTS reagent (Promega).
development is generally observed by day 15 after cell injection. On daysTo assay for IFN defects, cell lines were pretreated with either 5 units/ml
12, 14, and 16, mice were treated with 1  109 AV2 virus or 1  109 pfuof IFN- (Schering) or IFN- (PBL Biomedical) for 12 hr and then challenged
equivalent of UV-inactivated AV2 VSV by intraperitoneal injection. Mice werewith a range of doses of WT VSV as described above. A standard MTS
monitored for morbidity and euthanized upon development of ascites.assay was performed and the results compared from nonpretreated cells.
Subcutaneous tumor modelMicroarray
To establish subcutaneous tumors, 8- to 10-week-old Balb/C female miceOVCAR4 cells either mock treated or infected with WT and AV strains were
(Charles River) were shaved on the right flank and injected with 1  106harvested in PBS, pelleted, and resuspended in 250 l of resuspension
CT26 colon carcinoma cells (Kashtan et al., 1992) syngeneic for Balb/C mice.buffer (10 mM Tris [pH 7.4], 15 mM NaCl, 12.5 mM MgCl2). Six hundred
These tumors were allowed to develop until they reached approximately 10microliters of Lysis buffer (25 mM Tris [pH 7.4], 15 mM Nacl, 12.5 mM MgCl2
mm3, at which time virus treatments were initiated. Groups of animals re-5% sucrose, and 1% NP-40) was added and the lysates were incubated at
ceived 1 of 6 doses of the indicated virus every other day for 2 weeks. Each4C for 10 min with occasional vortexing. Nuclei were collected by centrifuga-
dose of 5  108 pfu was administered by tail vein infection. Tumors weretion at 1000  g for 3 min. The supernatant (cytoplasmic fraction) was
measured daily and volumes calculated using the formula 1/2(L*W*H). Micecollected and frozen at 80C while the pellet (nuclear fraction) was washed
were weighed daily and monitored for weight loss, dehydration, piloerection,once with 250 l of lysis buffer and frozen. Total RNA was isolated from
huddling behavior, respiratory distress, and hind limb paralysis. Animalsboth nuclear and cytoplasmic fractions using the Qiagen RNeasy kit (as
were euthanized when their tumor burden reached end point (750 mm3).per manufacturer’s instructions; Qiagen) followed by LiCl precipitation to
concentrate each sample. Twenty micrograms of each RNA sample was
processed according to manufacturer’s standard protocol (Affymetrix) and Lung model
hybridized to an Affymetrix HGA133u A chip. Each chip was scaled to 1500, Lung tumors were established in 8- to 10-week-old female Balb/C mice
normalized to the 100 normalization control genes present on each chip, (Charles River) by tail vein injection of 3  105 CT26 cells (Specht et al.,
then all nuclear samples were normalized to the mock nuclear sample on a 1997). On days 10, 12, 14, 17, 19, and 21, groups of mice received 5  107
per gene basis, while the cytoplasmic fractions were normalized to the pfu of the indicated virus by intranasal instillation as described elsewhere
corresponding mock cytoplasmic sample. Data were analyzed using Gene- (Stojdl et al., 2000a). Mice were weighed daily and monitored for weight
spring software (SiliconGenetics). loss, dehydration, piloerection, huddling behavior, respiratory distress, and
hind limb paralysis. Animals were euthanized at the onset of respiratory
distress and their lungs examined to confirm tumor development.Western blotting
OVCAR4 cells were grown in RPMI (Wisent) supplemented with 10% fetal
bovine serum (Wisent). 1  107 cells were plated in 10 cm dishes the day Visualization of GFP-expressing VSV strains in vivo
prior to infection. For infection, the media were removed and replaced with Female Balb/c mice (Charles River) were injected with 3  105 CT26 cells
RPMI alone prior to the addition of 5  107 pfu per VSV viral strain. One via the vein to initiate pulmonary metastases. On day 17, mice were injected
hour after virus addition, media were removed and replaced with RPMI intravenously with 2.5  108 pfu AV3 GFP VSV. Hind limb tumors were
supplemented with 10% FBS for the remaining duration of the experiment. seeded by subcutaneous injection with 3  105 CT26 cells. When tumors
Cells were lysed in standard NP-40 lysis buffer, and 75 g of whole-cell reached a volume of approximately 400 mm3, mice were injected intrave-
extract was run on SDS-polyacrylamide gel and blotted with the following nously with 2.5  108 pfu of AV3 GFP VSV. At the indicated times, mice
antibodies as indicated: IRF-7 (sc-9083; Santa Cruz), IRF-3 (sc-9082; Santa were euthanized and tumors examined using a Leica MZFLIII microscope
Cruz), ISG56 (a gift from Ganes Sen), VSV-N (polyclonal directed against with a standard GFP filter set. Pictures were captured with a Nikon Coolpix
the full-length Indiana N protein), and Actin (sc-8432; Santa Cruz). 100 camera. Overlayed images were generated using Adobe Photoshop 7.0.
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